Raul E Isturiz1, Julio Ramirez2, Wesley H Self3, Carlos G Grijalva4, Francis L Counselman5, Gregory Volturo6, Luis Ostrosky-Zeichner7, Paula Peyrani1, Richard G Wunderink8, Robert Sherwin9, J Scott Overcash10, Senen Pena Oliva2, Thomas File11, Timothy L Wiemken2, John M McLaughlin1, Michael W Pride12, Sharon Gray1, Ronika Alexander1, Kimbal D Ford1, Qin Jiang1, Luis Jodar1. 1. Pfizer, Inc. Collegeville, PA, USA. 2. Saint Louis University Center for Health Outcomes Research, St. Louis, MO, USA. 3. Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, USA. 5. Department of Emergency Medicine, Eastern Virginia Medical School, Norfolk, VA, USA. 6. Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, USA. 7. McGovern Medical School and Memorial Hermann Medical Center, Houston, TX, USA. 8. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 9. Department of Emergency Medicine, Wayne State University, Detroit, MI, USA. 10. eStudysite Clinical Research, Chula Vista, CA, USA. 11. Summa Health, Northeast Ohio Medical University, Akron, OH, USA. 12. Pfizer, Inc. Pearl River, NY, USA.
Abstract
BACKGROUND: Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. Further, most data regarding pneumococcal serotypes are derived from invasive pneumococcal disease (IPD), which represents only a fraction of all adult pneumococcal disease burden. Understanding which pneumococcal serotypes cause pneumonia in adults is critical for informing current immunization policy. The objective of this study was to measure the proportion of radiographically-confirmed (CXR+) community-acquired pneumonia (CAP) caused by PCV13 serotypes in hospitalized US adults. METHODS: This observational, prospective surveillance study recruited hospitalized adults aged ≥18 years from 21 acute care hospitals across 10 geographically-dispersed cities in the United States between October 2013 and September 2016. Clinical and demographic data were collected during hospitalization. Vital status was ascertained 30 days after enrollment. Pneumococcal serotypes were detected via culture from the respiratory tract and normally-sterile sites (including blood and pleural fluid). Additionally, a novel, Luminex-based serotype-specific urinary antigen detection (UAD) assay was used to detect serotypes included in PCV13. RESULTS: Of 15,572 enrolled participants, 12,055 eligible patients with CXR+CAP were included in the final analysis population. Mean age was 64.1 years and 52.7% were aged ≥65 years. Common comorbidities included chronic obstructive pulmonary disease (43.0%) and diabetes mellitus (28.6%). PCV13 serotypes were detected in 552/12,055 (4.6%) of all patients and 265/6347 (4.2%) of those aged ≥65 years. Among patients aged 18-64 years PCV13 serotypes were detected in 3.8-5.3% of patients depending on their risk status. CONCLUSIONS: After implementation of a pneumococcal conjugate vaccination program in US children, and despite the herd protection observed in US adults, a persistent burden of PCV13-type CAP remains in this population.
BACKGROUND: Few studies have measured the burden of adult pneumococcal disease after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into the US infant vaccination schedule. Further, most data regarding pneumococcal serotypes are derived from invasive pneumococcal disease (IPD), which represents only a fraction of all adult pneumococcal disease burden. Understanding which pneumococcal serotypes cause pneumonia in adults is critical for informing current immunization policy. The objective of this study was to measure the proportion of radiographically-confirmed (CXR+) community-acquired pneumonia (CAP) caused by PCV13 serotypes in hospitalized US adults. METHODS: This observational, prospective surveillance study recruited hospitalized adults aged ≥18 years from 21 acute care hospitals across 10 geographically-dispersed cities in the United States between October 2013 and September 2016. Clinical and demographic data were collected during hospitalization. Vital status was ascertained 30 days after enrollment. Pneumococcal serotypes were detected via culture from the respiratory tract and normally-sterile sites (including blood and pleural fluid). Additionally, a novel, Luminex-based serotype-specific urinary antigen detection (UAD) assay was used to detect serotypes included in PCV13. RESULTS: Of 15,572 enrolled participants, 12,055 eligible patients with CXR+CAP were included in the final analysis population. Mean age was 64.1 years and 52.7% were aged ≥65 years. Common comorbidities included chronic obstructive pulmonary disease (43.0%) and diabetes mellitus (28.6%). PCV13 serotypes were detected in 552/12,055 (4.6%) of all patients and 265/6347 (4.2%) of those aged ≥65 years. Among patients aged 18-64 years PCV13 serotypes were detected in 3.8-5.3% of patients depending on their risk status. CONCLUSIONS: After implementation of a pneumococcal conjugate vaccination program in US children, and despite the herd protection observed in US adults, a persistent burden of PCV13-type CAP remains in this population.
Authors: David Fitz-Patrick; Mariano Young; Daniel A Scott; Ingrid L Scully; Gary Baugher; Yahong Peng; Kathrin U Jansen; William Gruber; Wendy Watson Journal: Hum Vaccin Immunother Date: 2021-02-05 Impact factor: 3.452
Authors: Warren V Kalina; Victor Souza; Kangjian Wu; Peter Giardina; Andrew McKeen; Qin Jiang; Charles Tan; Roger French; Yanhua Ren; Kelly Belanger; Susan McElhiney; Manu Unnithan; Huiming Cheng; Terri Mininni; Donna Giordano-Schmidt; Bradford D Gessner; Kathrin U Jansen; Michael W Pride Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 9.079
Authors: Claire von Mollendorf; Mukhchuluun Ulziibayar; Bradford D Gessner; Lien Anh Ha Do; Cattram D Nguyen; Rohini Beavon; Bujinlkham Suuri; Dashtseren Luvsantseren; Dorj Narangerel; Adam Jenney; Eileen M Dunne; Catherine Satzke; Badarchiin Darmaa; Tuya Mungun; E Kim Mulholland Journal: BMC Public Health Date: 2021-09-23 Impact factor: 3.295
Authors: Jason LeBlanc; May ElSherif; Lingyun Ye; Donna MacKinnon-Cameron; Ardith Ambrose; Todd F Hatchette; Amanda Ls Lang; Hayley D Gillis; Irene Martin; Walter H Demczuk; Craig LaFerriere; Melissa K Andrew; Guy Boivin; William Bowie; Karen Green; Jennie Johnstone; Mark Loeb; Anne McCarthy; Allison McGeer; Makeda Semret; Sylvie Trottier; Louis Valiquette; Duncan Webster; Shelly A McNeil Journal: BMJ Open Respir Res Date: 2020-03
Authors: Hannah Lawrence; Harry Pick; Vadsala Baskaran; Priya Daniel; Chamira Rodrigo; Deborah Ashton; Rochelle C Edwards-Pritchard; Carmen Sheppard; Seyi D Eletu; David Litt; Norman K Fry; Samuel Rose; Caroline Trotter; Tricia M McKeever; Wei Shen Lim Journal: PLoS Med Date: 2020-10-23 Impact factor: 11.069